Data from EMC - Curated by Toby Galbraith - Last updated 31 January 2017

Indication(s)

- ABILIFY tablets
- ABILIFY orodispersible tablets
- ABILIFY oral solution:

ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.

ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.

ABILIFY is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.


- ABILIFY solution for injection:
ABILIFY solution for injection is indicated for the rapid control of agitation and disturbed behaviours in adult patients with schizophrenia or with manic episodes in Bipolar I Disorder, when oral therapy is not appropriate.

Treatment with ABILIFY solution for injection should be discontinued as soon as clinically appropriate and the use of oral aripiprazole should be initiated.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

Visit Prostate Cancer

More information

Category Value
Agency product number EMEA/H/C/000471
Orphan designation No
Date First Approved 04-06-2004
Type POM
Marketing authorisation holder Otsuka Pharmaceutical Europe Ltd.

Related Content